BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) cures many patients, but often with the risk of late effects and impaired quality of life. The value of quantifying patient-reported outcomes (PROs) is increasingly being recognized, but the routine collection of PROs is uncommon. This study evaluated the feasibility of prospective PRO collection by an outcome registry at multiple time points from unselected HCT patients undergoing transplantation at centers contributing clinical data to the Center for International Blood and Marrow Transplant Research (CIBMTR), and then it correlated the PRO data with clinical and demographic data. METHODS: The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), 36-Item Short Form Health Survey (SF-36), and Pediatric Quality of Life Inventory measures were administered before HCT, on day 100, and at 6 and 12 months. Patients were recruited by the transplant center, but posttransplant PRO collection was managed centrally by the CIBMTR. RESULTS: There were 580 eligible patients, and 390 (67%) enrolled. Feasibility was shown by high time-specific retention rates (176 of 238 at 1 year or 74%) and participant satisfaction. Factors associated with higher response rates were an age > 50 years (odds ratio [OR], 1.58; 95% confidence interval [CI], 1.03-2.41; P = .0355), white race (OR, 4.61; 95% CI, 2.66-7.99; P < .0001), and being married (OR, 2.28; 95% CI, 1.42-3.65; P = .0006) for adults and a higher family income for children (OR, 4.99; 95% CI, 2.12-11.75; P = .0002). Importantly, pre-HCT PRO scores independently predicted survival after adjustments for patient-, disease-, and transplant-related factors. The adjusted probabilities of 1-year survival were 56%, 67%, 75%, and 76% by increasing quartiles of the pre-HCT FACT-BMT score and 58%, 72%, 62%, and 82% by increasing quartiles of the pre-HCT SF-36 physical component score. CONCLUSIONS: A hybrid model of local consent for centralized PRO collection is feasible, and pretransplant PROs provide critical prognostic information for HCT outcomes. Cancer 2017;123:4687-4700.
BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) cures many patients, but often with the risk of late effects and impaired quality of life. The value of quantifying patient-reported outcomes (PROs) is increasingly being recognized, but the routine collection of PROs is uncommon. This study evaluated the feasibility of prospective PRO collection by an outcome registry at multiple time points from unselected HCT patients undergoing transplantation at centers contributing clinical data to the Center for International Blood and Marrow Transplant Research (CIBMTR), and then it correlated the PRO data with clinical and demographic data. METHODS: The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), 36-Item Short Form Health Survey (SF-36), and Pediatric Quality of Life Inventory measures were administered before HCT, on day 100, and at 6 and 12 months. Patients were recruited by the transplant center, but posttransplant PRO collection was managed centrally by the CIBMTR. RESULTS: There were 580 eligible patients, and 390 (67%) enrolled. Feasibility was shown by high time-specific retention rates (176 of 238 at 1 year or 74%) and participant satisfaction. Factors associated with higher response rates were an age > 50 years (odds ratio [OR], 1.58; 95% confidence interval [CI], 1.03-2.41; P = .0355), white race (OR, 4.61; 95% CI, 2.66-7.99; P < .0001), and being married (OR, 2.28; 95% CI, 1.42-3.65; P = .0006) for adults and a higher family income for children (OR, 4.99; 95% CI, 2.12-11.75; P = .0002). Importantly, pre-HCT PRO scores independently predicted survival after adjustments for patient-, disease-, and transplant-related factors. The adjusted probabilities of 1-year survival were 56%, 67%, 75%, and 76% by increasing quartiles of the pre-HCT FACT-BMT score and 58%, 72%, 62%, and 82% by increasing quartiles of the pre-HCT SF-36 physical component score. CONCLUSIONS: A hybrid model of local consent for centralized PRO collection is feasible, and pretransplant PROs provide critical prognostic information for HCT outcomes. Cancer 2017;123:4687-4700.
Keywords:
36-Item Short Form Health Survey (SF-36); Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT); patient-reported outcomes; survival; transplantation
Authors: R P McQuellon; G B Russell; D F Cella; B L Craven; M Brady; A Bonomi; D D Hurd Journal: Bone Marrow Transplant Date: 1997-02 Impact factor: 5.483
Authors: Margaret F Bevans; Sandra A Mitchell; John A Barrett; Michael R Bishop; Richard Childs; Daniel Fowler; Michael Krumlauf; Patricia Prince; Nonniekaye Shelburne; Leslie Wehrlen; Li Yang Journal: Biol Blood Marrow Transplant Date: 2013-12-17 Impact factor: 5.742
Authors: William A Wood; Jennifer Le-Rademacher; Karen L Syrjala; Heather Jim; Paul B Jacobsen; Jennifer M Knight; Muneer H Abidi; John R Wingard; Navneet S Majhail; Nancy L Geller; J Douglas Rizzo; Mingwei Fei; Juan Wu; Mary M Horowitz; Stephanie J Lee Journal: Cancer Date: 2015-10-06 Impact factor: 6.860
Authors: John R Wingard; I-Chan Huang; Kathleen A Sobocinski; Michael A Andrykowski; David Cella; J Douglas Rizzo; Marianne Brady; Mary M Horowitz; Michelle M Bishop Journal: Biol Blood Marrow Transplant Date: 2010-06-01 Impact factor: 5.742
Authors: Michael D Brundage; Katherine C Smith; Emily A Little; Elissa T Bantug; Claire F Snyder Journal: Qual Life Res Date: 2015-05-27 Impact factor: 4.147
Authors: William A Wood; Allison M Deal; Amy Abernethy; Ethan Basch; Claudio Battaglini; Yoon Hie Kim; Julia Whitley; Charlotte Shatten; Jon Serody; Thomas Shea; Bryce B Reeve Journal: Biol Blood Marrow Transplant Date: 2012-12-16 Impact factor: 5.742
Authors: Elissa T Bantug; Theresa Coles; Katherine C Smith; Claire F Snyder; Julie Rouette; Michael D Brundage Journal: Patient Educ Couns Date: 2015-11-02
Authors: Amy Cassedy; Dennis Drotar; Richard Ittenbach; Shawna Hottinger; Jo Wray; Gil Wernovsky; Jane W Newburger; Lynn Mahony; Kathleen Mussatto; Mitchell I Cohen; Bradley S Marino Journal: Health Qual Life Outcomes Date: 2013-06-18 Impact factor: 3.186
Authors: Li-Wen Huang; Ying Sheng; Charalambos Andreadis; Aaron C Logan; Gabriel N Mannis; Catherine C Smith; Karin M L Gaensler; Thomas G Martin; Lloyd E Damon; Michael A Steinman; Chiung-Yu Huang; Rebecca L Olin Journal: Biol Blood Marrow Transplant Date: 2019-09-05 Impact factor: 5.742
Authors: William A Wood; M Weaver; A E Smith-Ryan; E D Hanson; T C Shea; C L Battaglini Journal: Support Care Cancer Date: 2020-02-28 Impact factor: 3.603
Authors: Angela B Smith; Cleo A Samuel; Sean D McCabe; Allison Deal; Mattias Jonsson; Dana E Mueller; Zahra M Mahbooba; Antonia V Bennett; Arlene E Chung; Matthew E Nielsen; Hung-Jui Tan; Eric Wallen; Raj Pruthi; Andrew Wang; Ethan Basch; Bryce B Reeve; Ronald C Chen Journal: Urol Oncol Date: 2020-08-17 Impact factor: 3.498